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Abstract: There are currently multiple approaches to facilitate gene therapy via intramuscular gene
delivery, such as electroporation, viral delivery, or direct DNA injection with or without polymeric
carriers. Each of these methods has benefits, but each method also has shortcomings preventing
it from being established as the ideal technique. A promising method, ultrasound-mediated gene
delivery (or sonodelivery) is inexpensive, widely available, reusable, minimally invasive, and safe.
Hurdles to utilizing sonodelivery include choosing from a large variety of conditions, which are often
dependent on the equipment and/or research group, and moderate transfection efficiencies when
compared to some other gene delivery methods. In this review, we provide a comprehensive look at
the breadth of sonodelivery techniques for intramuscular gene delivery and suggest future directions
for this continuously evolving field.
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1. Introduction
Gene therapy shows increasing promise for the treatment of a wide range of diseases, from cancer
to musculoskeletal and immunological disorders [1]. Although the basic premise of gene therapy is
relatively simple on the surface—to introduce a gene or genes into a patient’s cells/tissue that will allow
the body to produce a therapeutic protein or facilitate a genetic modification—every step of the process
holds its own challenges. One of the major challenges associated with making gene therapy widely (and
safely) accessible is that of gene delivery in vivo. There are currently many methods for delivering DNA
in vitro at high efficiencies, including electroporation, lipid-based transfection, and viral delivery. Each
of these methods presents potential challenges for clinical translation, including the cost and time of
production, the invasiveness of the technique, the efficiency of delivery, and/or safety concerns related
to an immune response or unintended genomic integration of the therapeutic gene. The development of
a gene delivery technique that is inexpensive, widely available, reusable, minimally invasive, and safe
will catalyze progress in gene therapy. One promising technique that meets all of these criteria has been
under investigation for many years but has not yet reached widespread use: ultrasound-mediated
or sonoporation gene delivery, herein referred to as sonodelivery [2,3]. As its name suggests, this
approach involves using ultrasound to deliver non-viral vectors encoding therapeutic proteins into
skeletal muscle, allowing the body to then produce its own therapeutic. Despite the work that has been
done to explore the practicality of ultrasound-mediated intramuscular gene delivery, there is, to our
knowledge, no comprehensive review of the most common approaches and technical conditions used
for this promising technology. This review aims to fill that void and to discuss the future work needed
for and the potential of establishing sonodelivery as a key player in the gene therapy field.
Bioengineering 2020, 7, 107; doi:10.3390/bioengineering7030107 www.mdpi.com/journal/bioengineering
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2. Methods for Cellular and Intramuscular Gene Delivery
There are many established methodologies for delivering plasmid DNA (pDNA) to muscles,
each with its own advantages and disadvantages (Figure 1). To highlight these and provide context
for the importance of sonodelivery, we will provide a brief background on four of the most common
pDNA delivery approaches (excluding sonodelivery).
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Figure 1. Common approaches for delivery of plasmid DNA into skeletal muscle and their associated
advantages (green) and disadvantages (red).
2.1. Direct Injection of Naked DNA
The oldest and most basic method of intramuscular DNA delivery is injection of naked DNA
directly into the target muscle. This method yields a low immunogenic response i vivo an is both
wid ly availabl and inexpensive [4]. Plasmids are low-cost and low maintenance and intramuscular
injections are straightforward (though not necess ily easy) to dminister, making this method one of the
s mplest to pply. However, it suffers from a v ry low efficiency [5], which has prevented direct injection
of naked DNA fr m becoming a viable technique. It has been reported that swelling the muscles before
injection (e.g., pr treating with a hypertonic solution) improves expr ssion of proteins for which the
transfected genes code [4,6,7]. Simil rly, introducing myotoxic age ts to the target muscle a few days
prior to DNA injection has been shown to improve protei expression, but it is not yet clear whether
this improvement is due to improved uptake of naked DNA or improved gene expression following
uptake [4,8]. With all intramuscular gene delivery, injection technique is crucial [9]. A properly
localized injection at optimal depth is essential, but is increasingly challenging as the size of the in vivo
model increases [4]. Injections are therefore difficult to standardize, as optimal techniques require
training and extensive practice. One method that has been used to increase injection accuracy when
delivering a variety of payloads is the utilization of imaging ultrasound to guide the injection [10–13],
although this too requires expertise and extensive practice. Another complication associated with
increased test animal size is that of decreased gene uptake/expression. This may be due to increased
levels of connective tissue in larger animals, which either acts to disperse the naked DNA or as a
barrier to the DNA, preventing it from entering muscle cells [14]. Despite extensive research involving
direct injection of naked DNA, DNA uptake and protein expression levels remain low. Thus, efforts
to improve the efficiency of DNA delivery, including both biochemical and physical approaches,
have led to strategies utilizing polymer and nanoparticle coupling, viral vectors, and electroporation,
among others.
Bioengineering 2020, 7, 107 3 of 16
2.2. Polymers and Nanoparticles
Polymer and/or nanoparticle conjugation to DNA involves incubating DNA with the
polymer/nanoparticle sample prior to delivery to improve transfection efficiency. These particles,
if engineered with the appropriate properties, generally do not compromise cell viability or cause
significant immunogenicity [15]. Interestingly, several aspects of the polymer, such as molecular weight,
stability, size, charge, and structure, greatly affect the efficacy of the DNA binding and subsequent
delivery into cells [15]. The ability to change these factors through polymer engineering makes this
method highly adaptable; for example, polymers of a certain molecular weight might work well
for intramuscular gene delivery but be ineffectual when applied to hepatocytes. It is also of note
that polymers are often easy and inexpensive to synthesize [15]. Cationic polymers form so-called
“polyplexes” (polymer–DNA complexes) with DNA, by binding to negatively charged phosphate
groups in DNA, which facilitates the introduction of the DNA into the cell [16]. Despite their relative
ease of use and production, these formulations are still inferior to alternative gene delivery methods in
terms of efficiency (e.g., viral vectors), although they have been shown to approximate the efficiency of
viral vectors when used in combination with physical methods of gene delivery [17–19]. Additionally,
both degradable and non-degradable polymers have drawbacks that, to date, have complicated
clinical applications. Degradable polymers may lead to accumulation of toxic metabolites and adverse
reactions to treatment [20], whereas non-degradable polymers may aggregate during circulation and
present a risk of clotting [21,22].
2.3. Viral Vectors
Viral vectors boast some of the highest gene delivery efficiencies of any of the methods discussed
herein [10,23]. Multiple types of viruses are used in transfection, with adeno-associated viruses (AAVs)
among the most common, especially for delivering genetic material into muscle cells. Although
it is a significant challenge to produce good manufacturing practice (GMP) levels of virus at high
enough titers for clinical trials, localized and systemic gene transfer methods utilizing AAVs have
been developed, each with its own advantages and disadvantages [19,24]. Systemic viral delivery
(i.e., intravenous injection) poses great risk to patients due to potential immune response and off-target
delivery [13]. Localized delivery (i.e., direct intramuscular injection) tends to be much safer than
systemic delivery because it induces a lower level of immune response and has decreased off-target
delivery, but it is often less efficient for transducing large muscle masses due to the inability of the viral
vector to disperse throughout the muscle tissue. In tumors, it is possible to use oncolytic viruses that can
spread throughout the mass, but this would likely not be a safe approach for muscle. With appropriate
targeting, the risk of infecting surrounding healthy myocytes can be reduced, though not eliminated
entirely [25]. An additional risk of viral gene delivery is insertional mutagenesis. Through the process
of genomic integration, additional base pairs are introduced to the genome [26]; these unintentional
additions can be oncogenic and/or cause a great number of genetic defects. In summary, there are
a number of major challenges associated with the most commonly used viral vectors, from the
high risk for immunogenicity to the risk of (unintended) insertional mutagenesis to the high cost of
production [19,23,27].
2.4. Electroporation
Due to the immunogenicity risks associated with biochemical methods, physical approaches have
recently been investigated more extensively. One physical delivery method that is well integrated in
the gene delivery field is electroporation. There are a range of electroporation devices and techniques,
with many different products on the market to fit specific applications in vivo, in vitro, in situ,
and ex vivo. Electroporation tends to produce a high transfection efficiency in all applications [28].
Its mechanism of action lies in the permeabilization of the cell and nuclear membranes using
electricity [29]. The electrical current (“electro-”) creates transient pores (“-poration”) in the cell
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membrane through which genetic material can enter the cytoplasm [30]. The DNA can then move into
the nucleus through similar pores in the nuclear membrane. This method can be applied to any portion
of the body and is a relatively rapid process. One of the main challenges involved with electroporation
is the invasiveness of the technique in vivo; electrodes are typically inserted into the subject [13,31].
Another major challenge with electroporation is the resultant low cell viability in vivo [32]. Gaps in the
cell membrane can cause both an inflammatory response and necrosis of muscle fibers, which can lead
to muscle damage. Although there are many different settings that can be adjusted to dramatically
alter the uptake of DNA and/or viability of cells, electroporation still tends toward low viability [33].
Finally, electroporation is costly when compared to most other methods of physical gene delivery.
3. Ultrasound-Mediated Gene Delivery in Skeletal Muscle
Although each of the above-mentioned techniques has advantages and are helping to further
the progress of gene therapy, their disadvantages are significant. One promising solution for
delivering non-viral vectors to muscles for therapeutic protein production is ultrasound-mediated
intramuscular gene delivery (sonodelivery), with advantages pertaining to maximizing safety,
accessibility, and efficiency, while minimizing cost and invasiveness.
Sonodelivery is intramuscular gene delivery augmented with ultrasound to facilitate increased
uptake of DNA. Although some of the general mechanisms will be discussed herein, a description
of the basic methodology used for sonoporation will not be provided. We would encourage anyone
interested in a thorough description of in vitro and in vivo sonoporation methodologies to refer to the
previously published works available, including [13,34,35], among others.
3.1. Benefits of Ultrasound
Patient safety and therapeutic expense are two major factors to consider in any treatment type.
Consequently, ultrasound-based strategies hold great promise for gene delivery or other therapeutics,
due to their low cost and clinically established safety [13]. Ultrasound has been used on patients since
the late 1940s and has been considered safe for pregnant women since the 1950s [36]. More specifically,
the levels of ultrasound required for sonodelivery are also associated with low cytotoxicity levels and
minimal tissue damage in vitro and in vivo [2,37]. Although sonodelivery is typically performed with
specialized equipment, standard clinical ultrasound machines can be modified to produce the necessary
output [10,18,38,39]. Standard ultrasound equipment is widely available and reusable indefinitely,
making ultrasound a very affordable means of physical gene delivery.
An important consideration for a gene delivery system is its degree of invasiveness. As ultrasound
waves can penetrate deep tissue even when applied epicutaneously, it is a very minimally invasive
technique [3,40]. This combination of affordability, minimal invasiveness, and high level of safety
makes ultrasound an enticing option for clinical gene delivery.
3.2. Sonoporation In Vitro
Generally, biological methods are tested in vitro prior to performing in vivo studies. This has
been the case with sonoporation, with groups testing the efficacy of sonodelivery in various cell
types [34,41–43]. Prior studies indicate that the conditions for in vitro sonodelivery tend to vary
widely, from the settings of the sonoporator (Table 1) to the way cells are prepared for gene delivery
(e.g., in suspension or seeded in culture plates). This wide variance tends to lead to variable transfection
efficiencies. While it is common to experience problems when translating from in vitro to in vivo,
this problem is particularly pronounced for sonodelivery, making it very challenging to effectively
optimize conditions for intramuscular gene delivery using in vitro testing data [34,39,41,42]. There are
likely many factors leading to this, such as increased difficulty in creating pores in cells in vivo [41],
the rigid plastics that are used for cell culture causing ultrasound beam distortion issues [42] and
the creation of standing waves [39], differences in DNA accessibility in culture versus in the natural
muscle environment, and effectiveness of cell repair mechanisms in a monoculture. Other factors may
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also include the in vivo structure being more “protective” of the cells or the body’s ability to recruit
inflammatory cells to the muscle following sonoporation.
Table 1. Examples of common in vitro sonoporation conditions. Conditions listed are representative
of the preferred conditions for pDNA delivery in the referenced experiment, not representative of
all conditions tested. PRF = pulse repetition frequency; “-“ = not reported; * = unpublished data;







(%) Duration (s) Cell Type Reference
KTAC-4000 1.015 0.7 - 50 360 C2C12 Our Group *
KTAC-4000 2 2.5 2 50 10 COS-7 [44]
Sonidel SP100 1 2 100 60 450 HeLa [42]
Sonidel SP100 1 4 - 60 450 C2C12 Our Group *
Panametrics 2.25 - 100 20 10 MAT B III [45]
ES-1 Ultrasonic Generator 1 3.6 - - 20 PC3 [41]
“Dedicated Continuous Wave System” 1 0.75 - - 30 VSMC, HUVEC [39]
Mark 3, EMS Limited ** 1 0.8 100 20 20 H2K Myoblast [46]
UltraMax ** 1 2 100 30 1800 BHK, LNCaP, BCE [47]
We expect sonoporation to eventually become an inexpensive, reusable option for transfecting
cells, especially following optimization and commercialization of specific tools designed to augment
sonoporation in vitro. A significant challenge is the lack of well-defined sonodelivery conditions
employed in vitro across laboratories (Table 1). This, combined with the lack of in vitro–in vivo
correlation, establishes the necessity of further sonodelivery research, especially in vivo. Particularly
notable is that, in our experience, in vivo sonoporation is more effective than in vitro sonoporation.
As such, we will focus this review on in vivo sonodelivery work, as it appears to share more similarities
across laboratories on how skeletal muscle sonoporation is approached and performed and we
anticipate that it will have the greatest impact on the field of gene therapy.
3.3. Skeletal Muscle as a Therapeutic “Factory”
Although sonodelivery could be used to deliver genes in vivo for short-term treatment therapies
such as targeted gene editing systems (e.g., CRISPR/Cas9), to deliver a therapeutic protein or drug
directly to the site of interest [48,49], or to deliver viral vectors [50] or siRNA [51,52], this review will
focus primarily on the delivery of plasmid DNA for long-term protein production.
Unlike injecting a dose of a drug that will be metabolized relatively quickly, genetic material must
remain in the body long enough to allow for protein production and for the therapeutic protein to
reach levels sufficient to treat a patient’s condition. Their low turnover, high metabolic rate, and ability
to secrete cytokines and proteins (myokines) make skeletal muscle cells ideal candidates for protein
production, particularly secreted proteins with therapeutic activity. Skeletal muscle’s inherent ability to
repair itself using progenitor cells (i.e., satellite cells) could also provide a potential healing mechanism
for any localized toxicity or inflammation induced during gene delivery [29,53,54]. The concept of gene
therapy, to use a patient’s own tissue to create a therapeutic by delivering genes coding for therapeutic
proteins, relies heavily on the tissue’s ability to produce these proteins over time. Skeletal muscle,
which makes up approximately 30% of and provides structure and stability throughout the entire adult
human body [55], is a promising target for therapeutic protein production because its cells tend to live
longer than other cell types. A muscle can effectively become a “factory” within the body, continuously
producing therapeutic proteins for months at a time [56,57] if the vector enables long-term expression.
The therapeutic proteins produced at the factory can then be delivered systemically [43,55,58], allowing
for long-term treatment following a single dose of intramuscular gene delivery [59]. Fusing specific
motifs to the protein can further facilitate targeted delivery, for example, thus increasing therapeutic
effectiveness and safety by decreasing off-target accumulation [60].
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3.4. Sonoporation in Skeletal Muscle
Sonoporation has been proven effective for delivering pDNA into cells and tissues, especially
when used in tandem with microbubbles (MBs) [19,38,43,61,62]. In studies using firefly luciferase as a
reporter gene, pDNA, supplemented with MBs, was delivered successfully to muscles in vivo and
the luciferase protein was expressed at high levels (nearly 100-fold higher than the non-ultrasound
control) for prolonged periods of time (Figure 2) [10]. To our knowledge, studies have only shown
localized luciferase activity in muscle cells at or near the injection site, with no indications of off-target
delivery, accumulation, or expression [39].
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form of Luciferase) in vivo. Mice were injected once with 50 μg plasmid DNA (DNA and DNA + 
ultrasound (US) groups), or 50 μg plasmid DNA premixed with 5 × 105 microbubbles (DNA + 
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kPa for 2 min (DNA + US and DNA + MBs + US group). The treatment effect was monitored using 
bioluminescence imaging for 21 days after treatment. ****, p< 0.05 relative to control. (B–E). 
Representative images obtained in each group (DNA, DNA + MBs, DNA + US, and DNA + MBs + US, 
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(Reprinted from Shapiro et al. [10] with permission.) 
Figure 2. Luciferase 2 (Luc2) expression time course following sonoporation in vivo. (A). Luciferase
expression profile in mice treated with microbubble-enhanced sonoporation of Luc2 (an enhanced form
of Luciferase) in vivo. Mice were injected once with 50 µg plasmid DNA (DNA and DNA + ultrasound
(US) groups), or 50 µg plasmid DNA premixed with 5 × 105 microbubbles (DNA + microbubbles
(MBs) and DNA + MBs + US groups) and then treated with an acoustic pressure of 200 kPa for 2 min
(DNA + US and DNA + MBs + US group). The treatment effect was monitored using bioluminescence
imaging for 21 days after treatment. ****, p < 0.05 relative to control. (B–E). Representative images
obtained in each group (DNA, DNA + MBs, DNA + US, and DNA + MBs + US, respectively) on
Day 4 with the region of interest indicated by a red oval. Color bar, p/s/cm2/sr. (Reprinted from
Shapiro et al. [10] with permission.)
One of the key components for successful sonoporation in muscle in vivo is the addition of
MBs [10,19,38,43,62]. MBs are common echo-contrast agents used in medical procedures in humans.
They typically consist of an inert gaseous bubble encapsulated by a biocompatible material, with lipids
being the most common interfacial encapsulant [13,63]. For sonodelivery, MBs can either be fabricated
with a protein or gene of interest loaded within the bubble or “empty” bubbles can be complexed
with the payload prior to injection [64]. Examples of microbubbles used for sonoporation include
SonoVueTM (Bracco), which has a phospholipid shell surrounding sulfur hexafluoride, and Optison
(GE Healthcare), which consists of albumin-encapsulated perfluoropropane [65,66]. It is not fully
understood how sonodelivery works at the cellular level, but it is generally believed that ultrasound
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energy produces transient micropores in the cell membrane via cavitation caused by oscillation of
small bubbles present in the ultrasound media [2,43,45,55,67,68]. It is further believed, and empirically
supported, that the addition of MBs significantly increases the cavitation facilitated by ultrasound
alone (Figure 3) [13,43]. It has also been suggested that MBs create a microjet stream when they rupture,
which forces the bound (or encapsulated) pDNA (or protein) into the cells through the pores created
by the ultrasound-induced cavitation [44,64]. Regardless of the mode of action, it has been shown
repeatedly that the addition of MBs significantly increases payload delivery into skeletal muscle as
well as other types of tissue [10,19,55,61,69–72].
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Figure 3. Electron microscope images of human skeletal muscles transfected with Optison MBs and
pDNA with or without US. Micropores can be seen immediately following transfection (white arrow).
(Reprinted from Taniyama et al. [43] with permission.)
While combi ng ultrasound and MBs ffectively delivers luciferase DNA into muscle, delivery
of other types of DNA is problematic, possibly due to inefficient DNA uptake into the nucleus from
the cytoplasm. While this would not be problematic for protein delivery, DNA must be taken into
the nucleus for protein production to occur. One way to overcome this is by incorporating polymers
with a nuclear localization sequence (NLS). A previous study conducted by our group showed that
sonodelivery of DNA combined with MBs and an NLS-tagged polymer did indeed increase the
efficiency of plasmid uptake and subsequent protein produ tion by as much as six times compared to
the non-US control [17] (Figure 4). On the other hand, ome untargeted polymers, such as P85 Pluronic
block copolymer, combined with MBs and ultrasound, showed a ~2-fold increase in pDNA delivery
when compared to the non-ultrasound control [18]. Although further work is needed to determine the
best polymer properties and ratio to MBs and pDNA and to determine the ideal ultrasound settings to
deliver the polymer/MBs/pDNA mixture, this approach holds great promise for improving the efficacy
of intramuscular so o elivery. NLS polymers with variable compositions to balance hydro hilicity
and charge are curre tly under devel pment with the objective of further enhancing sonodelivery
in muscle.
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Figure 4. Intramuscular ultrasound-mediated g n delivery or “s nodelivery” in mice by NLSc- and
rNLSd-based polyplexes. (A) R presentative biolumin s nce images of mice transf cted with a
luciferas reporter plasmid after a 5 in using a Xenogen IVIS100 C D camera (9 days
after sonoporati n). The right h nd legs represent protei expression resulting from intramuscular
ultraso nd-mediated elivery; the left hind legs represent intramuscular delivery in th absence of
ultrasound. The color bar indicates the luminescence tensity i photons per second per square
centim ter per steradian (p/s/cm2/sr). (B) Luciferase expression from right hind legs. (C) Percentage
change in luciferase expression u on application of an ultrasound stimul s (the ratio of t e expression
from the right hind leg to t at from the left hind l g). Bars indicate ± the standard error of th mean
(error b rs) with * p < 0.05 for the rNLSd 12.5 µg dose as compar d to all other gr ups. (R printed with
permission from Parelkar et al. [17]. Copyright (2014) American Chemical Society.)
3.5. Effects of Sonoporation on Skeletal Muscle
Studies focused on how skeletal muscle is affected by sonoporation further demonstrate that it
is one of the safest methods for gene delivery in vivo. For example, Chen et al. showed that muscle
damage was comparably minimal following MB-free DNA injection with or without polymer and with
or without ultrasound. When MBs were combined with ultrasound, there was a statistically significant
increase in muscle damage compared to the control (Figures 5 and 6). The authors noted that the damage
was always localized around the injection site even when gene expression was observed distally [18].
In a similar study conducted by our group, muscles that had been injected with a DNA/MBs/polymer
mixture and then subjected to ultrasound showed no significant damage at any of the time points
evaluated during the study: 7 days, 23 days, or 12 months (Figure 7) [59]. Two other studies, conducted
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by Shapiro et al. and Wang et al., support our findings, with results showing no significant damage to
muscles following treatment with MBs, DNA, and ultrasound [10,38]. Interestingly, a study conducted
by Lu et al. yielded results contradictory to those of Chen et al., in that muscle damage was decreased
in mice treated with DNA, MBs, and ultrasound compared to mice treated with DNA only [19]. Overall,
these results are promising, especially in comparison to electroporation, which consistently induces
muscle damage [29,73]. If we also consider the remarkable ability of skeletal muscle to repair itself from
minor damage by employing progenitor (satellite) cells [53,54], the damage caused by sonoporation
may not have a significant adverse impact on muscle fibers.
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Figure 7. Analysis of muscle damage following gene delivery. Histological analyses at 7 days, 23 days,
and 12 months, indicate neither plasmid, pCpGF (A) nor pEPIto (B), produced any significant signs
of damage, as shown by H&E staining and visualization of skeletal muscle at 200× magnification.
Inset: selected areas at higher magnification to show nuclear positioning in muscle fibers. Scale bar
represents 50 µm. Arrows: normal positioning of nuclei at the periphery of muscle fibers, F; arrowheads:
occasional atypical nuclei positioned centrally within fibers. (C) Analyses of percentage of muscle
fibers displaying atypical central nuclei show no significant differences (p > 0.3) for either plasmid
group for all three time points. (Reprinted from Figueiredo Neto et al. [59] with permission.)
3.6. Variability in Sonoporation Conditions
Another factor that may lead to discrepancies between luciferase delivery and delivery of other
types of DNA is variability in sonoporation conditions. Other variables may include the type of
luciferase gene used (firefly, Renilla, enhanced firefly, etc.), the promoter driving transcription of
the gene and other vector-related properties, the composition of the MB stabilizer (polymer, lipid,
etc.), the concentration of MBs, and whether or not polymers are used in the nanoplex formulation.
As was shown in Table 1, most research groups tend to use different sonoporation conditions in vitro.
Table 2 shows that this is further accentuated for in vivo work. There are also a variety of different
sonoporators in use, with many being custom modified ultrasound instruments. Although there
are some commonalities among the different techniques, there is no consensus on an “ideal” set of
conditions. Conditions used are largely dependent on each research group’s empirically derived
preferences and the equipment used for the experiment. Although each research group has had success
with their chosen sonoporation method, these differences could contribute to the disparity of results
in the efficiency of sonodelivery and subsequent protein production. Developing a standardized
protocol could help to bring defined sonoporation-mediated gene therapy conditions to the clinical
stage. On the other hand, the success of sonodelivery under a variety of conditions highlights its
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potential application in a variety of clinical scenarios. For example, patients of different demographic
groups (especially age) will likely have different levels of muscle density, so the ability to adapt the
ultrasound conditions for each patient could increase the reach of sonodelivery.
Table 2. Examples of optimized in vivo sonoporation conditions. The conditions listed are representative
of the preferred conditions for pDNA delivery in the referenced experiment; they are not representative
of all conditions tested. PRF = pulse repetition frequency; “-“ = not reported; * = unpublished data;
+ = not listed in work, but based on work carried out by same reference group.





1 3 1000 20 60 [74]
KTAC-4000 1.015 3 - 20 60 Our Group *
Sonidel SP 100 1 2 - 50 180 Our Group *
Sonidel SP 100 1 1.9 - 25 360 [42]
Sonidel SP 100 1 2 - 25 180 [75]
Sonigene 1 3 - 20 60 [76]
Sonigene 1 2 - 20 60 [17]
Sonitron 2000 1 0.4 200 20 1200 [55,77]
Sonitron 2000 1 5 - 50 600 [78]
Sonitron 2000 1 4 - 50 300 (60 * 5) [79]
Sonopore 3000 2 2.5 2 50 60 [51]
Therapeutic Instruments
Mark 3, EMS Limited 1 1 - 20 120 [18]
Mark 3, EMS Limited+ 1 3 100 20 60 [19]
Mark 3, EMS Limited 1 2 100 20 30 [38]
Modified Siemens
Antares 1.4 - 540 - 120 [10]
Ultax UX-301+ 1 2.5 - - 60 [43]
UltraMax 1 1.5 - 30 120 [80]
System V, GE Vingmed 1.7 Mechanical Index = 1.7 180 [39]
4. Future Directions
The most pressing future direction for sonodelivery is that of standardization. With so many
different sonoporators and sonoporation conditions, even for the same target tissue or cell type, and with
such disparity in the results of the gene delivery, it is difficult to determine a standardized treatment
method. Developing a standard unit of measure could help to expedite this process. Sonoporation
conditions are typically reported by duty cycle, frequency, time, and intensity. Many reports also
include probe size and some reports include other conditions, ranging from wave type to power output.
Unfortunately, with the differences between instruments, the conditions that are typically reported can
lead to a variable power output, meaning that the delivery power is likely not the same, even if the
conditions are very similar. Although more optimization clearly is needed to find the average optimal
conditions for delivering DNA into muscle using sonoporation, establishing a standard method for
reporting sonoporation conditions, such as the inclusion of the power output, which can be calculated
for each set of conditions, may help to ameliorate some of the disparities in results.
An interesting future direction for the sonodelivery field would include more work on combining
sonoporation with other approaches that might increase the efficacy of gene delivery. Some work has
already been done along this vein, including polymer-mediated sonodelivery [17,18,59], adjustments to
cell membrane permeability by adding enzymes, such as hyaluronidase [80], and by adding drugs such
as lidocaine and adjusting temperature [41], and electro-sonoporation [58,81,82]. Electro-sonoporation
is a particularly interesting procedure in which electroporation and sonoporation are applied
simultaneously to facilitate cell membrane pore formation. In a proof of concept investigation,
Longsine-Parker et al. found that cell viability was 97.3% and membrane pore formation efficiency was
95.6% in mammalian cells after application [82]. These promising results were further explored with
in vitro and in vivo studies that found that electro-sonoporation performed significantly better in both
transfection efficiency and cell viability compared to electroporation alone [58,81]. While more work is
needed to confirm these results and elaborate on the effectiveness of electro-sonoporation, it appears to
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be a highly promising technique. While all these possible adaptations would add more conditions to
consider in the standardization procedure, they could greatly enhance the efficacy of sonodelivery for
gene therapy.
Another direction of high importance and interest for intramuscular sonoporation will be the
delivery of therapeutic genes, as opposed to reporter genes (i.e., luciferase). Although sonoporation
has been used to deliver therapeutic genes intratumorally [62,76], the majority of the intramuscular
sonodelivery completed to date has utilized reporter genes to test sonoporation conditions and
efficiency. It could be argued that testing the delivery of therapeutic genes via sonoporation is of
greater importance than standardization, as having a standardized method will only be useful when
sufficient levels of therapeutic expression are observed. To help mitigate the potential for non-standard
conditions to be a confounding factor of a lack of therapeutic expression, this work could be conducted
in tandem with the above-mentioned standardization work. Of particular interest would be the
delivery of therapeutic proteins tagged or fused with a reporter gene, such as luciferase, which would
allow for simultaneous testing of therapeutic expression and optimization of sonodelivery conditions.
Further improvements for intramuscular sonodelivery and gene therapy might include the
incorporation of muscle-specific refinements of payload, such as microbubbles designed to target
skeletal muscle or the extracellular matrix (ECM) or vectors containing skeletal muscle-specific
promoters to increase the efficiency of transgene expression [83]. In light of all these considerations,
it can easily be seen that there is additional optimization needed for these approaches and there would
be great benefit to the scientific community in implementing more extensive testing of therapeutic
delivery to skeletal muscle using sonoporation.
5. Conclusions
As gene therapy becomes more popular as a viable therapeutic strategy, an affordable, non-invasive,
non-viral gene delivery system will help to increase its availability and safety. Ultrasound-mediated
gene delivery can fill this niche and, with continued study and proper standardization, sonodelivery
has the potential to become the predominant technique for intramuscular gene delivery.
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